Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 5,801–5,900 of 15,747
SARS-CoV-2 Omicron-specific mRNA vaccine induces potent and broad antibody responses in vivo
Fang, Z., Peng, L., Lin, Q., Ren, P., Suzuki, K., Xiong, Q., Clark, P., Lin, C.-X., & Chen, S. (2022) · bioRxiv · doi:10.1101/2022.02.14.480449
de la Cruz, M. L., Pardilla, M. B. E., Sánchez, M. G., Rodríguez, L. G., Muner, M., Royuela, A., Recarte, P. P., Martínez‐Varea, A., Martínez‐Diago, C., Melguizo, S. C., et al. (2021) · Vaccines · doi:10.3390/vaccines9010031 · Cited by 14
Great Expectations of COVID-19 Herd Immunity
Giurgea, L. T., & Morens, D. M. (2022) · mBio · doi:10.1128/mbio.03495-21 · Cited by 16
The Impact of the Global COVID-19 Vaccination Campaign on All-Cause Mortality
Agrawal, V., Sood, N., & Whaley, C. (2023) · National Bureau of Economic Research · doi:10.3386/w31812 · Cited by 20
“While data from clinical trials suggested that vaccines are safe and effective (Polack et al. 2020; Baden et al. 2021; Voysey et al. 2021), the real-world effectiveness of COVID-19 vaccines in averting deaths might differ from clinical trial evidence for a variety of reasons.”
Sullivan, D. J., Focosi, D., Hanley, D. F., Cruciani, M., Franchini, M., Ou, J., Casadevall, A., & Paneth, N. (2022) · medRxiv · doi:10.1101/2022.05.24.22275478 · Cited by 14
“Sotrovimab United States, Canada, Brazil, and Spain 1057 1057 53(1796) 571 (54) 919 (87) 42 (4) 687 (65) 211(20) 1055 (99.”
BackgroundInfluentialRevolutionizing cancer treatment: the rise of personalized immunotherapies
Fayyaz, A., Haqqi, A., Khan, R., Irfan, M., Khan, K., Reiner, Ž., Sharifi‐Rad, J., & Călina, D. C. (2024) · Discover Oncology · doi:10.1007/s12672-024-01638-1 · Cited by 22
Marc, G. P., Álvarez-Paggi, D., & Polack, F. P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150135 · Cited by 16
Self-citationO'Brien, M. P., Forleo-Neto, E., Sarkar, N., et al. (2021) · medRxiv · doi:10.1101/2021.06.14.21258569 · Cited by 16
Fazio, N. D., Delogu, G., Bertozzi, G., Fineschi, V., & Frati, P. (2022) · Vaccines · doi:10.3390/vaccines10020216 · Cited by 15
“The National Drug Adverse Event Reporting Network will be a key focus because, as a result of the preliminary findings of the three-stage testing [13], it allows the recording of a considerable amount of information about a given drug.”
BackgroundAbbadessa, G., Lavorgna, L., Trojsi, F., Coppola, C., & Bonavita, S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1957673 · Cited by 16
“Although the initial findings from the Covid-19 vaccine trials [80] are encouraging, no people with MS were included”
BackgroundYang, Y., Ivanov, D. G., & Kaltashov, I. A. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03601-3 · Cited by 16
Zepeda–Cervantes, J., Martínez-Flores, D., Ramírez‐Jarquín, J. O., Tecalco-Cruz, Á. C., Alavez-Pérez, N. S., Vaca, L. A., & Silva, R. E. S. (2022) · Viruses · doi:10.3390/v14010094 · Cited by 21
Haemophagocytic lymphohistiocytosis following COVID-19 mRNA vaccination
Wu, V., López, C. A. G., Hines, A., & Barrientos, J. C. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-247022 · Cited by 15
Chen, M., Venturi, V., & Munier, C. M. L. (2023) · Biology · doi:10.3390/biology12071035 · Cited by 18
“, in the phase 2 clinical trial, the protective effect elicited by vaccination was induced as early as 12 days following first dose of BNT162b2 mRNA vaccine in a large study cohort, as measured by a lower rate of occurrence of COVID-19 cases observed in the vaccine group compared to the placebo group [11].”
BackgroundImmune Responses against SARS-CoV-2—Questions and Experiences
Mangge, H., Kneihsl, M., Schnedl, W. J., Sendlhofer, G., Curcio, F., & Domenis, R. (2021) · Biomedicines · doi:10.3390/biomedicines9101342 · Cited by 16
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
Tandler, C., Heitmann, J. S., Michel, T., Marconato, M., Jaeger, S. U., Tegeler, C. M., Denk, M., Richter, M., Oezbek, M. T., Maringer, Y., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.11.009 · Cited by 16
Glycolipid nanoparticles target the spleen and detarget the liver without charge
Gentry, K., Lian, L., Kim, H., Celik, O., Jones, C., Podilapu, A. R., Shakked, A., Loughrey, D., Zenhausern, R., Jang, B., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409569122 · Cited by 18
(2021) · doi:10.21203/rs.3.rs-343388/v1 · Cited by 272
Predictors of Mortality Among Hospitalized COVID-19 Patients at a Tertiary Care Hospital in Ethiopia
Ayana, G. M., Merga, B. T., Birhanu, A., Alemu, A., Negash, B., & Dessie, Y. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s337699 · Cited by 15
Egberink, R. O., Zegelaar, H. M., Boujnouni, N. E., Versteeg, E. M. M., Daamen, W. F., & Brock, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081619 · Cited by 16
Reporting of Allergic Reactions During Pfizer-BioNTech BNTT162B2 Vaccination in Israel
Anis, E., Alroy‐Preis, S., Cedar, N., Tal, Y., Hershkowitz, I., & Hershko, A. Y. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.07.012 · Cited by 15
“Using this scoring system, we obtained these findings: (1) only 8% of all events are likely allergic reactions and the rate increases to 36% to 41% among subjects reported as severe allergy; (2) a previous allergy may increase the likelihood of immediate reaction reporting without affecting validated anaphylaxis; and…”
Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Schmidt, A. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.539332 · Cited by 15
Rai, C.-I., Kuo, T.-H., & Chen, Y. (2024) · Vaccines · doi:10.3390/vaccines12091002 · Cited by 22
Calendario de vacunaciones de la Asociación Española de Pediatría: Recomendaciones 2022
García, F. J. Á., Ortega, M. J. C., Aldeán, J. Á., Garcés‐Sánchez, M., Llanos, E. G., de Arce, A. I., Melián, A. M., Gómez, M. L. N., Solas, V. P., Calle, I. R., et al. (2022) · Anales de Pediatría · doi:10.1016/j.anpedi.2021.11.003 · Cited by 18
Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies
Muthukutty, P., MacDonald, J., & Yoo, S. Y. (2024) · Vaccines · doi:10.3390/vaccines12111220 · Cited by 20
The Role of Exosomes in the Treatment, Prevention, Diagnosis, and Pathogenesis of COVID-19
Zani‐Ruttenstock, E., Antounians, L., Khalaj, K., Figueira, R. L., & Zani, A. (2021) · European Journal of Pediatric Surgery · doi:10.1055/s-0041-1731294 · Cited by 17
García, M. T. M., Lana, Á. T., Agudo, M. B. A., et al. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.03.008 · Cited by 15
Liu, J., Mao, Q., Wu, X., He, Q., Bian, L., Bai, Y., Wang, Z., Wang, Q., Zhang, J., Liang, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.814365 · Cited by 17
Álvarez, M. M., Bravo-González, S., & Santiago, G. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254430 · Cited by 15
“50 efficacy, as demonstrated through clinical trials [5]), they require administration of two doses in a time frame of 21 or 30 days to reach a protection of 95% [5].”
BackgroundCombating Infectious Diseases with Synthetic Biology
Khan, A., Ostaku, J., Aras, E., & Şeker, U. Ö. Ş. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00576 · Cited by 17
Elmorsy, M. A., El-Baz, A. M., Mohamed, N. H., Almeer, R., Abdel‐Daim, M. M., & Yahya, G. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16427-4 · Cited by 16
Tong, D., Zhang, M., Yang, Y., Xia, H., Tong, H., Zhang, H., Zeng, W., Liu, M., Wu, Y. L., Ma, H., et al. (2022) · Protein & Cell · doi:10.1093/procel/pwac020 · Cited by 15
“Many vaccines have been developed for the control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, including vaccines based on messenger RNA (mRNA) (Polack et al. 2020), viral vectors (Zhu et al.”
BackgroundNi, W., Li, W., Cai, Z., Guo, W., Zheng, Y., Zhao, Y., Wu, Z., Liang, S., Ye, J., Guo, X., et al. (2024) · Journal of Virology · doi:10.1128/jvi.01516-24 · Cited by 21
Containing the spread of mumps on college campuses
Shah, M., Ferra, G., FitzGerald, S. F., et al. (2022) · Royal Society Open Science · doi:10.1098/rsos.210948 · Cited by 15
Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina
Uschner, D., Bott, M., Santacatterina, M., Gunaratne, M., Fette, L. M., Burke, B., Strylewicz, G., Edelstein, S. L., Lagarde, W. H., MILLER, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10111922 · Cited by 19
Alva, C., Vidaković, I., Lorber, B., Schachner-Nedherer, A.-L., Zettl, M., Khinast, J., Prassl, R., & Hsiao, W. (2022) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-022-09643-z · Cited by 14
“Indeed, the recent vaccines developed by BioNTech/Pfizer and Moderna, which use LNPs as delivery vehicles for mRNA targeting the SARS-CoV-2 spike protein, represented a turning point in the fight against the COVID-19 pandemic [10, 12–14].”
BackgroundBohnert, A. S. B., Kumbier, K. E., Rowneki, M., Gupta, A. B., Bajema, K. L., Hynes, D. M., Viglianti, E. M., O’Hare, A. M., Osborne, T. F., Boyko, E. J., et al. (2023) · BMJ · doi:10.1136/bmj-2022-074521 · Cited by 15
Coudeville, L., Jollivet, O., Mahé, C., Chaves, S. S., & Gomez, G. B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250797 · Cited by 16
“Strong supply constraint Hospitalizations averted 5,569 [4,966;5,889] 7,664 [6,565;7,887]”
BackgroundWu, X., Lin, J., Buch, H., Ding, Q., Zhang, F., Cui, B., & Ji, G. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.731578 · Cited by 15
Araste, F., Bakker, A. D., & Zandieh‐Doulabi, B. (2023) · Journal of Nanoparticle Research · doi:10.1007/s11051-023-05867-3 · Cited by 18
“Dermal side effects, such as erythema or swelling, are slightly more common with mRNA vaccines than with adenoviral vaccines (10–15% versus 5–7% of the patients) [134–136].”
BackgroundHasanpourghadi, M., Novikov, M., Ambrose, R., Chekaoui, A., Newman, D., Ding, J., Giles‐Davis, W., Xiang, Z., Zhou, X., Liu, Q., et al. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2022.105082 · Cited by 15
“Two doses of mRNAvaccines are initially over 90% effective in preventing symptomatic disease [2,3].”
Kang, W. C. M., Shami, J. J. P., Yan, V. K. C., Ye, X., Blais, J. E., Li, X., Lee, V. H.-F., Chui, C. S. L., Lai, F. T. T., Wan, E. Y. F., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01265-9 · Cited by 16
Benin, A. L., Soe, M. M., Edwards, J. R., et al. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.08.004 · Cited by 14
Wnorowska, S., Targowska‐Duda, K. M., Kurzepa, J., et al. (2022) · Industrial Crops and Products · doi:10.1016/j.indcrop.2022.115338 · Cited by 14
Meerasa, S. S., Ahmad, A., Khan, A. A., Haque, S., & Saleem, I. Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126263 · Cited by 16
Brehm, T. T., Thompson, M., Ullrich, F., Schwinge, D., Addo, M. M., Spier, A., Knobloch, J. K. ‐., Aepfelbacher, M., Lohse, A. W., Lütgehetmann, M., et al. (2021) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2021.113851 · Cited by 13
Murugesan, K., Jagannathan, P., Altamirano, J., Maldonado, Y., Bonilla, H. F., Jacobson, K. B., Parsonnet, J., Andrews, J. R., Shi, R., Boyd, S. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac045 · Cited by 16
Executable network of SARS-CoV-2-host interaction predicts drug combination treatments
Howell, R. S. M., Clarke, M. A., Reuschl, A., Chen, T., Abbott-Imboden, S., Singer, M., Lowe, D. M., Bennett, C. L., Chain, B., Jolly, C. L., et al. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00561-5 · Cited by 18
Ethical issues in managing the COVID‐19 pandemic
Raus, K., Mortier, E. P., & Eeckloo, K. (2021) · Bioethics · doi:10.1111/bioe.12877 · Cited by 13
Kudriavtsev, A. V., Vakhrusheva, A., Kryuchkov, N. A., Frolova, M. E., Blagodatskikh, K. А., Ivanishin, T. V., Djonovic, M., Romanovskaya-Romanko, E., Kovalenko, A. N., Lioznov, D. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020326 · Cited by 14
Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose
Lustig, Y., Gonen, T., Meltzer, L., et al. (2021) · medRxiv · doi:10.1101/2021.12.19.21268037 · Cited by 12
Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination
Sekulovski, M., Mileva, N. B., Vasilev, G., Miteva, D., Gulinac, M., Peshevska-Sekulovska, M., Chervenkov, L., Batselova, H., Vasilev, G., Tomov, L., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102813 · Cited by 15
Chew, M. C., Wiryasaputra, S., Wu, M., Khor, W., & Chan, A. S. Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.925683 · Cited by 14
“Although the serological data for these patients is unavailable, it is likely that the first dose served to prime the immune system and the cumulative effects resulted in a shift in the B cell and CD8+ T cell population that may have triggered the autoimmune flare or reactivation of the latent infections (46).”
BackgroundBeaudoin-Bussières, G., Tauzin, A., Dionne, K., Gendron‐Lepage, G., Medjahed, H., Perreault, J., Levade, I., Alfadhli, L., Bo, Y., Bazin, R., et al. (2023) · Viruses · doi:10.3390/v15061274 · Cited by 16
Early atypical injection‐site reactions to COVID‐19 vaccine: a case series
Vaccaro, M., Bertino, L., Squeri, R., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17683 · Cited by 14
Alcohol use disorder in the COVID‐19 era: Position paper of the Italian Society on Alcohol (SIA)
Testino, G., Vignoli, T., Patussi, V., Allosio, P., Amendola, M. F., Aricò, S., Baselice, A., Balbinot, P., Campanile, V., Fanucchi, T., et al. (2021) · Addiction Biology · doi:10.1111/adb.13090 · Cited by 14
Homan, T., Mazzilli, S., Chieti, A., Musa, A., Roth, A., Fortunato, F., Bisceglia, L., Prato, R., Lopalco, P. L., & Martinelli, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-23235-4 · Cited by 16
Tyner, H. L., Burgess, J. L., Grant, L., Gaglani, M., Kuntz, J. L., Naleway, A. L., Thornburg, N. J., Caban-Martinez, A. J., Yoon, S. K., Herring, M. K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1038 · Cited by 14
“The superior immunogenicity of two doses of mRNA vaccine compared to a single dose in real-world conditions is consistent with findings from efficacy trials [10, 11] and other recent observational studies [7].”
ResultThe impact of the Covid-19 pandemic on quality of life in skin cancer patients
Kurzhals, J. K., Klee, G., Busch, H. S., Hagelstein, V., Zillikens, D., Terheyden, P. A. M., & Langan, E. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255501 · Cited by 14
“Whilst the development of vaccines promises to dramatically alter the course of the pandemic in the medium to long term and may reassure patients, especially those in risk groups, that the disease can be brought under control [3, 5] little is known about the specific impact of Covid-19 on the quality of life in patien…”
BackgroundZhou, X., Wang, H., Ji, Q., Du, M., Liang, Y., Li, H., Li, F., Shang, H., Zhu, X., Wang, W., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00840-z · Cited by 14
Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19
Saleem, A., Akhtar, M. F., Haris, M., & Abdel‐Daim, M. M. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00850-7 · Cited by 15
Subjective Feelings of Polish Doctors after Receiving the COVID-19 Vaccine
Zdziarski, K., Landowski, M., Zabielska, P., & Karakiewicz, B. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126291 · Cited by 16
“Overall, the incidence of adverse events was low and similar in both study groups [1].”
BackgroundResultFigueroa‐Espada, C. G., Guimarães, P. P. G., Riley, R., Xue, L., Wang, K., & Mitchell, M. J. (2023) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-023-00774-y · Cited by 14
“One example of the clinical translation of NPs is the NP-based mRNA vaccines against COVID-19, developed by Moderna and Pfizer/BioNTech [29], which received FDA emergency use authorization in 2020.”
BackgroundKolesov, D., Sinegubova, M. V., Dayanova, L. K., Dolzhikova, I. V., Vorobiev, I. I., & Orlova, N. A. (2022) · Diagnostics · doi:10.3390/diagnostics12020393 · Cited by 16
“It is widely assumed that neutralizing antibodies prevent re-infection with SARS-CoV-2 in recovered people or first infection in immunized people, and such antibodies may help treat patients with severe COVID-19.”
BackgroundInfluentialRevisiting the endocrine and metabolic manifestations of COVID-19 two years into the pandemic
Giustina, A., & Bilezikian, J. P. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09716-x · Cited by 15
“As a result of an unprecedented world-wide effort, vaccination against COVID-19 has become universally available [38].”
BackgroundYe, F., Majumder, S., Jiang, W., Li, X., Balakrishnan, N., Zhang, Y., & Deen, M. J. (2022) · IEEE Internet of Things Journal · doi:10.1109/jiot.2022.3199216 · Cited by 18
“The efficacy of the vaccine varies from 66% to 95% [94], [95].”
BackgroundMyocarditis following COVID-19 vaccination
Kaul, R., Sreenivasan, J., Goel, A., Malik, A. H., Bandyopadhyay, D., Jin, C., Sharma, M., Levine, A., Pan, S., Fuisz, A., et al. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100872 · Cited by 14
“The messenger ribonucleic acid (mRNA) - based BNT162b2 (Pfizer, Inc) and mRNA-1273 vaccines (Moderna, Inc) were demonstrated in large randomized clinical trials to be highly effective in preventing severe illness from COVID-19 and to have acceptable safety profiles [1,2].”
COVID-19 mRNA Vaccine-induced Pneumonitis
Matsuzaki, S., Kamiya, H., Inoshima, I., Hirasawa, Y., Tago, O., & Arai, M. (2021) · Internal Medicine · doi:10.2169/internalmedicine.8310-21 · Cited by 15
“The Pfizer-BioNTech COVID-19 vaccine BNT 162b2, a lipid nanoparticle-formulated nucleoside-modified RNA vaccine, was shown to be 95% effective in preventing COVID-19 (15) and treating a wide range of COVID-19related outcomes (16).”
BackgroundShioda, K., Breskin, A., Harati, P. M., Chamberlain, A. T., Komura, T., Lopman, B. A., & McQuade, E. T. R. (2024) · Nature Communications · doi:10.1038/s41467-024-45334-8 · Cited by 21
Cheung, M., Chang, C. W., Rathnasinghe, R., Rossignol, E. D., Zhang, Y.-F., Ferrari, A., Patel, H., Huang, Y., Guillen, M. A. S., Scalzo, T., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00747-2 · Cited by 21
Covid-19 vaccine immunogenicity in people living with HIV-1
(2021) · doi:10.1101/2021.08.13.456258 · Cited by 14
Prior, J. T., Limbert, V. M., Horowitz, R. M., D’Souza, S. J., Bachnak, L., Godwin, M. S., Bauer, D. L., Harrell, J. E., Morici, L. A., Taylor, J. J., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00677-z · Cited by 13
Lipid conjugate dissociation analysis improves the in vivo understanding of lipid-based nanomedicine
van Os, W. L., Wielaert, L., Alter, C. L., Davidović, D., Šachl, R., Kock, T. J. F., González, U. U., Arias‐Alpizar, G., Vigario, F. L., Knol, R. A., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.034 · Cited by 18
Disseminated varicella-zoster virus infections following messenger RNA–based COVID-19 vaccination
Said, J. T., Virgen, C. A., Lian, C. G., et al. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.09.008 · Cited by 14
“mRNA: messenger RNA VZV: varicella-zoster virus INTRODUCTION The novel messenger RNA (mRNA)ebased COVID-19 vaccines protect individuals from SARSCoV-2 infection and severe forms of the disease.(1) Clinical trials data and observational evidence have reported diverse cutaneous responses to these vaccines, including loc…”
Xue, W., Li, T., Gu, Y., Li, S., & Xia, N. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2227699 · Cited by 21
“…LNPs are favored in the field of nucleic acid delivery and have been utilized in the mRNA-based COVID-19 vaccines, BNT162b2 developed by BioNTech and Pfizer and mRNA-1273 developed by Moderna, both of which have demonstrated excellent immunogenic effects in clinical trials [155,156].”
MethodApaydın, H., Erden, A., Güven, S. C., Armağan, B., Konak, H. E., Polat, B., Afşin, Y., Kaygisiz, M., Omma, A., & Küçükşahin, O. (2022) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14387 · Cited by 14
Hoy, A., Zheng, Y. Y., Sheng, J., & Royzen, M. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0065 · Cited by 14
Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine
Ou, M. T., Boyarsky, B. J., Zeiser, L. B., Chiang, T. P., Ruddy, J. A., Rasmussen, S. E. V. P., Martin, J., Russell, J. S. C., Durand, C. M., Avery, R. K., et al. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001171 · Cited by 16
Giesen, N., Busch, E., Schalk, E., Beutel, G., Rüthrich, M. M., Hentrich, M., Hertenstein, B., Hirsch, H. H., Karthaus, M., Khodamoradi, Y., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.030 · Cited by 15
The Arrhythmogenic Face of COVID-19: Brugada ECG Pattern in SARS-CoV-2 Infection
Zimmermann, P. A., Aberer, F., BRAUN, M. U., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9040096 · Cited by 14
“In this context, fever episodes were reported by 11 and 16% in older and younger mRNA Comirnaty vaccine recipients, respectively, after the second dose [64,65].”
BackgroundPeptides: potential delivery systems for mRNA
Liang, H., Xing, Y., Wang, K., Zhang, Y., Yin, F., & Li, Z. (2025) · RSC Chemical Biology · doi:10.1039/d4cb00295d · Cited by 16
Trigueros, M., Pradenas, E., Palacín, D., Muñoz-López, F., Ávila‐Nieto, C., Trinité, B., Bonet, J. M., Isnard, M., Moreno, N., Marfil, S., et al. (2022) · Age and Ageing · doi:10.1093/ageing/afac101 · Cited by 16
Peptide-Decorated Degradable Polycarbonate Nanogels for Eliciting Antigen-Specific Immune Responses
Stickdorn, J., Czysch, C., Medina‐Montano, C., Stein, L., Xu, L., Scherger, M., Schild, H., Grabbe, S., & Nuhn, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015417 · Cited by 16
Characteristics and outcomes among vaccinated lung transplant patients with breakthrough COVID‐19
Bollineni, S., Mahan, L. D., Duncan, P., Mohanka, M. R., LAWRENCE, A. C., JOERNS, J. O., Timofte, I., Torres, F., Hoz, R. M. L., Kershaw, C. D., et al. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13784 · Cited by 14
A case report: symptomatic pericarditis post-COVID-19 vaccination
Ashaari, S., Sohaib, H. A., & Bolger, K. (2021) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytab375 · Cited by 14
“A study published in the New England Journal of Medicine (NEJM) has showed that two-dose regimen of BNT162b2 (Pfizer-BioNTech) has 95% efficacy for protection against COVID-19 in the persons 16 years of age or older.(7) The Centers for Disease Control and Prevention has recently reported the increase in cases of myoca…”
BackgroundANCA-associated vasculitis following the CoronaVac vaccination
Ma, Y., Huang, T., & Xu, G. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221125708 · Cited by 14
Nakayama, T., Sawada, A., & Ito, T. (2022) · Microbiology and Immunology · doi:10.1111/1348-0421.13043 · Cited by 15
Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNAPreprint
Lewis, M. M., Beck, T. J., & Ghosh, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.09.565872 · Cited by 18
“…(LNPs) have arisen as excellent carriers to facilitate encapsulation and intracellular delivery of therapeutic nucleic acids, as exemplified by their clinical approval for treating hereditary transthyretin-mediated amyloidosis 3 and for their more recent rapid approval for SARS CoV-2 4,5 .”
BackgroundMessage in a bottle: mRNA vaccination for influenza
Shartouny, J. R., & Lowen, A. C. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001765 · Cited by 17
“The BNT162b2 SARS- CoV2 mRNA vaccine contains the sequence of the spike protein with mutations that maintain it in a pre- fusion conformation [24].”
BackgroundIshii, T., Hamada, K., Jubishi, D., Hashimoto, H., Okamoto, K., Hisasue, N., Sunohara, M., Saito, M., Shinohara, T., Yamashita, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36397-6 · Cited by 15
Jiang, X., Sparks, J. A., Wallace, Z. S., Deng, X., Li, H., Lu, N., Xie, D., Wang, Y., Zeng, C., Lei, G., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002839 · Cited by 16
Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy
Wahab, S., Ghazwani, M., Hani, U., Hakami, A. R., Almehizia, A. A., Ahmad, W., Ahmad, M. Z., Alam, P., & Annadurai, S. (2023) · Molecules · doi:10.3390/molecules28031216 · Cited by 16
COVID-19 and hepatic injury: Diversity and risk assessment
Ali, F. E. M., El‐Aziz, M. K. A., Ali, M. M., Ghogar, O. M., & Bakr, A. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i3.425 · Cited by 17
Nie, X., Liu, Y., Song, Y., Yao, X., Chen, Y., Lee, H., & Gao, X. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady6730 · Cited by 23
A Review on COVID-19 Vaccinations
Garg, K., Talwar, D., Mahajan, S. N., Karim, S., Prajapati, K., Patel, S., & Garg, B. (2022) · Biomedical and Biotechnology Research Journal (BBRJ) · doi:10.4103/bbrj.bbrj_280_21 · Cited by 14
Chen, C., Fu, F., Ding, L., Fang, J., & Xiao, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938322 · Cited by 17
“COVID19 mRNA vaccines have been shown to be safe based on data from large-scale trials (1, 2).”
BackgroundMethodInfluentialRiddler, S. A., Moodie, Z., Clark, J. L., Yen, C., Allen, M., Furch, B. D., Lu, H., Grant, S., Mondal, K., Anderson, M., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02701 · Cited by 18
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.